// App-Quantinova.ai

: CaboCombo: A prospective international non-interventional study of first-line cabozantinib plus nivolumab for the treatment of patients with advanced renal cell carcinoma.

Researchers

Presenter

  • Philippe Barthelemy

Principal Investigators

  • Pascale Dutailly

  • Bryan Qvick

  • Valérie Perrot

  • Elena Verzoni

Medical Centers

  • Institut de Cancérologie Strasbourg Europe,Strasbourg, France, Strasbourg, France

  • Ipsen, Boulogne-Billancourt, France

  • TRION Pharma GmbH, Munich, Germany

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Locations

  • Italy

  • Germany

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

  • Renal cell carcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

  • Nivolumab

Outcome

  • N/A

Study Design

  • Non Interventional

  • Multinational

  • Prospective

Phase

  • III

Study Id's

  • NCT05361434

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved